LITTLE KNOWN FACTS ABOUT ERASTIN FERROPTOSIS.

Consequently, It is far from tough to conclude that erastin treatment ends in ROS manufacturing followed by p53 activation which subsequently activates the p53 downstream pathway. More importantly, this method forms a responses loop: erastin leads to a rise in ROS, which then leads to the activation of p53, which subsequently, causes improved ROS.